|
SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma Clinical research trials and SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma. SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma clinical trial. Participants oftentimes recieve the most expert healthcare available for their SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma  SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma
SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma
For Condition: Renal Cell Carcinoma
Status: Recruiting
Sponsor(s): Pfizer ,
Synopsis: The purpose of this study is to test whether SU-011,248 has activity and is safe in patients with Renal Cell Carcinoma (RCC).
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Histologically proven renal cell carcinoma of clear cell histology with metastases - Evidence of measurable disease by radiographic technique - Radiographic evidence of disease progression during or within 9 months of completion of 1 cytokine therapy (IL-2, IFN, or IL-2 + IFN) for at least 28 days - Prior nephrectomy - Male or female, 18 years or older - ECOG performace status of 0 or 1 - Resolution of all acute toxicitites of prior therapies - Adequate organ function - No prior treatment with any systemic therapy other than 1 cytokine therapy - No prior surgery, radiation, or systemic therapy within 4 weeks - No diagnosis of a second malignancy within the last 5 years - No known brain metastases, spinal cord compression or carcinomatous meningitis - No known HIV or AIDs related illness - No serious acute or chronic illness or recent history of significant cardiac abnormality - No uncontrolled hypertension
Total Enrollment: 100
Location and Contact Information:
Pfizer Investigational Site *Recruiting*
Portland, Oregon, 97213
United States
Recruiting
Pfizer Investigational Site *Recruiting*
New York City, New York, 10022
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Ann Arbor, Michigan, 48109
United States
Recruiting
Pfizer Investigational Site *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting
Pfizer Investigational Site *Recruiting*
San Francisco, California, 94115
United States
Recruiting
Pfizer Investigational Site *Recruiting*
New York City, New York, 10021
United States
Recruiting
Additional Information:
Study ID Numbers: A6181006;
Study Start Date: February 2004
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00077974
Other Renal Cell Carcinoma Studies:
1. A Phase II Protocol of Flt3 Ligand in Patients with Metastatic Melanoma and Renal Cancer
2. Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA
3. Stem Cell Transplant for Advanced Renal Cell Cancer
4. Survival Study Of Oncophage® vs. Observation In Patients with Kidney Cancer
5. Treatment of Patients with Metastatic Renal Cell Carcinoma with Neutralizing Antibody to Vascular Endothelial Growth Factor (VEGF)
Related Studies:
Other Renal Cell Carcinoma Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials
SU-011,248 in the Treatment of Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma
|
|
|
|
|
|
|
|
